Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1841-1860 of 2,251 trials

Multiple Myeloma: [68Ga]Ga-PentixaFor Imaging Study

We are exploring a new imaging method to see how well it detects multiple myeloma lesions in patients at diagnosis or relapse. This study may help improve the way we monitor and treat this condition.

Multiple Myeloma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

Pulmonary Arterial Hypertension>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

HPV-Negative Head and Neck Cancer: PARP Inhibitor and Immunotherapy Study

We are investigating a new treatment combining a PARP inhibitor and immunotherapy for patients with HPV-negative head and neck cancer. The study aims to see how well this treatment works and its safety compared to standard options.

Oropharyngeal Squamous Cell CarcinomaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Alagille Syndrome: Long-Term Study of Livmarli

We are examining the long-term safety and effectiveness of Livmarli in patients with Alagille Syndrome. This study will help us understand how well the treatment works and its tolerability over time.

Alagille Syndrome>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyHepatologyInternal Medicine

Nivolumab for ALK+ Anaplastic Large Cell Lymphoma

We are studying the effects of nivolumab in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma. This trial looks at its effectiveness for those with progressive disease and as a follow-up treatment for those in remission.

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Head and Neck Cancer: Nivolumab and Ipilimumab Study

We are studying the effects of nivolumab alone and in combination with ipilimumab after surgery for head and neck cancer. This trial aims to see if these treatments can help patients stay cancer-free and how they affect quality of life.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: MK-3120 Treatment Study

We are testing a new treatment called MK-3120 for people with advanced solid tumors to see how safe it is and if it can help reduce tumor size.

Advanced Solid Tumor Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

CAR-T Cell Therapy for Autoimmune Diseases

We are studying a new CAR-T cell treatment for patients with active autoimmune diseases like lupus, systemic sclerosis, and inflammatory myopathy. The trial aims to assess safety and how well this therapy works in reducing disease symptoms.

Systemic SclerosisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathy6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyNeurologyRheumatology

Baricitinib for Children Hospitalized with COVID-19

We are studying how the medication baricitinib works in children aged 1 to under 18 years who are hospitalized with COVID-19. This research aims to ensure the safety and proper dosing for young patients.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

CD19+ Lymphoid Disease: CAR T-Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.

Acute Lymphoblastic Leukemia (ALL) RecurrentNon-Hodgkin's Lymphoma (NHL) Refractory>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

B-Cell Malignancies: MB-CART2219.1 Therapy

We are testing a new CAR T-cell therapy for adults and children with relapsed or refractory B-cell cancers. The study aims to find the right dose and evaluate its safety and effectiveness.

Relapsed/Refractory Lymphoma or ALL>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Ovarian Cancer: Olaparib Maintenance Therapy

We are studying the effects of Olaparib as a maintenance treatment for patients with newly diagnosed advanced ovarian cancer. This trial aims to understand its safety and how it may improve patient outcomes.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Ovarian Cancer: Olaparib Treatment Study

We are investigating the effects of Olaparib in patients with recurrent ovarian cancer who do not have BRCA mutations. The goal is to see if it helps maintain treatment benefits after initial therapy and to understand its safety and effectiveness.

Recurrent Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Recurrent Ovarian Cancer: Olaparib vs. Chemotherapy

We are studying whether olaparib can help patients with recurrent ovarian cancer live longer without disease progression after surgery, compared to standard chemotherapy. The trial also looks at safety and quality of life.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Solid Tumors: Valemetostat Tosylate with DXd ADCs

We are studying a new combination treatment for patients with solid tumors to evaluate its safety and effectiveness. This trial aims to find better options for managing cancer.

Solid TumorSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology